A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.

Oddbjørn Straume,Cornelia Schuster,Gro Gausdal,James B. Lorens,Bjørn Tore Gjertsen

A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.

2018

Oddbjørn Straume
Cornelia Schuster
Gro Gausdal
James B. Lorens
Bjørn Tore Gjertsen

9548Background: Upregulation of the receptor tyrosine kinase Axl has been linked with both a reduced response to PD-1 blockade and the development of therapy resistance to BRAF directed therapies i...

Keywords:

Melanoma
Small molecule
Trametinib
Dabrafenib
Pembrolizumab
Pathology
Cancer research
Medicine
in patient
Downregulation and upregulation
Blockade
Receptor tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations